Opendata, web and dolomites

PharmaLedger SIGNED

PharmaLedger

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PharmaLedger project word cloud

Explore the words cloud of the PharmaLedger project. It provides you a very rough idea of what is the project "PharmaLedger" about.

records    supplies    data    providers    companies    patients    electronic    serve    source    governance    successful    privacy    documented    medicines    solutions    chain    platform    entire    innovative    marketplaces    efficiency    sustainability    universities    smes    industry    clinical    healthcare    counterfeit    designed    accelerating    digitization    integrity    truth    pharmaceutical    actionable    benefit    pharmaledger    learning    adoption    limited    ecosystem    single    extant    prioritized    innovation    health    trusted    recruitment    service    connectivity    submission    institutes    efficient    create    validation    big    stakeholders    framework    28    regulation    technologies    enabled    brings    decentralized    leveraging    business    ensured    interoperability    supply    combating    trials    manufacturers    security    compliance    evolutionary    11    methodology    specializing    pharmacoeconomic    medical    reference    machine    analytics    blockchain    tracking    intelligence    standards    patient   

Project "PharmaLedger" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD POLITECNICA DE MADRID 

Organization address
address: CALLE RAMIRO DE MAEZTU 7 EDIFICIO RECTORADO
city: MADRID
postcode: 28040
website: www.upm.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 20˙920˙901 €
 EC max contribution 8˙290˙693 € (40%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD POLITECNICA DE MADRID ES (MADRID) coordinator 873˙750.00
2    ROMSOFT SRL RO (IASI) participant 1˙157˙500.00
3    TECHNOVATIVE SOLUTIONS LTD UK (MANCHESTER) participant 910˙625.00
4    ARTEEVO TECHNOLOGIES LTD IL (TEL AVIV) participant 906˙250.00
5    PDM E FC PROJECTO DESENVOLVIMENTO MANUTENCAO FORMACAO E CONSULTADORIALDA PT (LISBOA) participant 648˙125.00
6    ONORACH LTD UK (DUNDEE) participant 511˙568.00
7    EKON MODELING SOFWARE SYSTEMS LTD*EKON IL (Modi'in-Maccabim-Re'ut) participant 456˙250.00
8    NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CRYOGENICS AND ISOTOPIC TECHNOLOGIES ICSI RM VALCEA RO (RAMNICU VALCEA) participant 370˙000.00
9    IMPRENSA NACIONAL - CASA DA MOEDA, S. A. PT (LISBOA) participant 365˙625.00
10    HOSPITAL DO ESPIRITO SANTO DE EVORA EPE PT (EVORA) participant 351˙250.00
11    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 347˙500.00
12    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 338˙500.00
13    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 307˙500.00
14    ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS EL (THERMI THESSALONIKI) participant 282˙500.00
15    DIMOKRITIO PANEPISTIMIO THRAKIS EL (KOMOTINI) participant 216˙250.00
16    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 143˙750.00
17    EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE BE (BRUSSELS) participant 103˙750.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
20    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
21    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
22    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
23    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
24    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
25    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
26    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
27    PFIZER LIMITED UK (SANDWICH) participant 0.00
28    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients. PharmaLedger will serve as a single source of truth for the healthcare ecosystem and will be designed for efficient decentralized governance, wide adoption by the stakeholders of the ecosystem, compliance with extant and emerging standards and regulation, and end-to-end connectivity and interoperability. Sustainability of the platform will be ensured by leveraging existing, successful blockchain technologies; open source reference implementation; and a fully documented, actionable methodology for evolutionary digitization of the healthcare industry. The project will address the key challenges of the healthcare ecosystem through prioritized delivery of applications and validation of business use cases, including but not be limited to end-to-end product tracking for combating counterfeit medicines and medical supplies; supply chain integrity; efficiency of recruitment and submission in clinical trials; and machine-learning health data marketplaces. The platform will support integrated use of medical devices across the use cases. The PharmaLedger project brings together 28 partners from 10 EU Member States, including 11 large pharmaceutical companies; highly innovative technology SMEs specializing in blockchain development, security, privacy and business intelligence; universities and research institutes specializing in pharmacoeconomic analysis, research of patient requirements, big data analytics and electronic health records; leading clinical trials companies; supply chain partners; patient representatives; and leading healthcare service providers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMALEDGER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMALEDGER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More